completed2022-10-15D series

Faricimab

Neovaskuläre altersabhängige Makuladegeneration

Open official case page ↗

Brand: Vabysmo
Manufacturer: Roche Pharma AG

G-BA action

final resolution

2023-06-27

Arzneimittel-Richtlinie/Anlage XII: Faricimab (Neovaskuläre altersabhängige Makuladegeneration) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2023-06-27. The official page states that it took effect as follows: 29.06.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 5956 →

Patient group

Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration (nAMD)

Added benefit not proven

Comparator
− Ranibizumab oder Aflibercept

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2023-02-20

77 parsed turns

Oral hearing: Faricimab (Neovaskuläre altersabhängige Makuladegeneration)

Official Wortprotokoll · 11 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A22-110

matched

Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V

Official assessment PDF · 42 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

2 decision

2023-04-06

final resolution

Arzneimittel-Richtlinie/Anlage XII: Faricimab (Neovaskuläre altersabhängige Makuladegeneration)

The G-BA found no proven added benefit for Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration (nAMD). The appropriate comparator was − Ranibizumab oder Aflibercept. The G-BA issued a final resolution on 2023-04-06. The official page states that it took effect as follows: 06.04.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

4 official documents · 4 cited claims

Open decision →

2023-06-27

final resolution